Abstract
miRNA plays a pivotal role in cancer diagnosis, biomarker development, and therapeutic interventions. With advancements in non-invasive diagnostics and personalized medicine, miRNA offers significant potential for clinical applications. Future research should focus on miRNA's role in drug resistance and combination therapies to accelerate its clinical translation.
Introduction
MicroRNAs (miRNAs)—small, non-coding RNA molecules that regulate gene expression—are critical drivers of tumor growth, metastasis, and drug resistance. Over the last decade, the volume of miRNA research has expanded exponentially, making it challenging to synthesize the overall trajectory of the field. This study provides a comprehensive bibliometric "map" of research from 2014 to 2024 across four major malignancies: colorectal cancer (CRC), prostate cancer, leukemia, and brain tumors. By analyzing over 24,000 publications, the authors identify a significant shift from basic gene expression studies toward clinical applications, specifically non-invasive "liquid biopsies" and personalized combination therapies.
Methodology and Data
The researchers employed a systematic bibliometric approach to analyze the scientific literature. Using databases to query publications between 2014 and 2024, they identified 24,801 relevant articles. The dataset was distributed as follows:
- Colorectal Cancer (CRC): 9,153 articles
- Prostate Cancer: 6,466 articles
- Leukemia: 5,524 articles
- Brain Tumors: 3,658 articles
Tools such as VOSviewer and CiteSpace were used to visualize co-citation networks, collaboration patterns, and "keyword bursts"—sudden spikes in term frequency that signal emerging trends.
Publication Trends and Global Leadership
The analysis revealed distinct trends in publication volume over the decade. CRC research emerged as the dominant powerhouse, peaking in 2021 with over 1,000 papers. In contrast, while brain tumor research volume remained lower, it has shown a recent uptick in interest regarding the tumor microenvironment.
Geographically, research is increasingly concentrated in China and the United States. China leads in publication volume for CRC and prostate cancer, with institutions like Nanjing Medical University and Shanghai Jiao Tong University emerging as global leaders. The US maintains a strong presence, particularly in high-impact leukemia and brain tumor research.
Key Insights: From Basic Biology to Clinical Application
A major finding of this study is the evolution of research focus. Early in the decade (2014–2016), "expression profiles" were the primary concern. By 2020–2024, the "hottest" keywords shifted to "extracellular vesicles," "circular RNA," and the "tumor microenvironment."
This shift signals the rise of the "liquid biopsy"—moving from studying miRNA inside cells to analyzing them in extracellular vesicles (EVs) found in blood and urine. This transition highlights the field's pivot toward non-invasive diagnostics. For instance, miR-21 and miR-92a have been identified as strong candidates for early-stage CRC detection.
The study also noted differences in network maturity. Leukemia research is highly centralized around influential figures, suggesting a more established field. Conversely, brain tumor research appears more fragmented, indicating it is still in an exploratory stage of development.
Future Directions and the Translation Gap
Despite the wealth of research, a "translation gap" remains; the movement of miRNA mimics or inhibitors into approved clinical drugs is slow. The authors suggest that the next frontier lies in combination therapy—using miRNAs to sensitize tumors to traditional chemotherapy or immunotherapy—and utilizing nanotechnology for precise drug delivery. Future efforts must focus on overcoming these hurdles to realize the full potential of miRNA in precision medicine.
Summary updated